A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Myeloid and Monocytic Leukemia
What is the purpose of this trial?
To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.
- Trial withAstex Pharmaceuticals, Inc.
- Start Date01/19/2021
- End Date10/01/2021
- Last Updated07/15/2021
- Study HIC#2000026338